Cargando…
Imipramine blocks acute silicosis in a mouse model
BACKGROUND: Inhalation of crystalline silica is associated with pulmonary inflammation and silicosis. Although silicosis remains a prevalent health problem throughout the world, effective treatment choices are limited. Imipramine (IMP) is a FDA approved tricyclic antidepressant drug with lysosomotro...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5594487/ https://www.ncbi.nlm.nih.gov/pubmed/28893276 http://dx.doi.org/10.1186/s12989-017-0217-1 |
_version_ | 1783263212285722624 |
---|---|
author | Biswas, Rupa Trout, Kevin L. Jessop, Forrest Harkema, Jack R. Holian, Andrij |
author_facet | Biswas, Rupa Trout, Kevin L. Jessop, Forrest Harkema, Jack R. Holian, Andrij |
author_sort | Biswas, Rupa |
collection | PubMed |
description | BACKGROUND: Inhalation of crystalline silica is associated with pulmonary inflammation and silicosis. Although silicosis remains a prevalent health problem throughout the world, effective treatment choices are limited. Imipramine (IMP) is a FDA approved tricyclic antidepressant drug with lysosomotropic characteristics. The aim of this study was to evaluate the potential for IMP to reduce silicosis and block phagolysosome membrane permeabilization. METHODS: C57BL/6 alveolar macrophages (AM) exposed to crystalline silica ± IMP in vitro were assessed for IL-1β release, cytotoxicity, particle uptake, lysosomal stability, and acid sphingomyelinase activity. Short term (24 h) in vivo studies in mice instilled with silica (± IMP) evaluated inflammation and cytokine release, in addition to cytokine release from ex vivo cultured AM. Long term (six to ten weeks) in vivo studies in mice instilled with silica (± IMP) evaluated histopathology, lung damage, and hydroxyproline content as an indicator of collagen accumulation. RESULTS: IMP significantly attenuated silica-induced cytotoxicity and release of mature IL-1β from AM in vitro. IMP treatment in vivo reduced silica-induced inflammation in a short-term model. Furthermore, IMP was effective in blocking silica-induced lung damage and collagen deposition in a long-term model. The mechanism by which IMP reduces inflammation was explored by assessing cellular processes such as particle uptake and acid sphingomyelinase activity. CONCLUSIONS: Taken together, IMP was anti-inflammatory against silica exposure in vitro and in vivo. The results were consistent with IMP blocking silica-induced phagolysosomal lysis, thereby preventing cell death and IL-1β release. Thus, IMP could be therapeutic for silica-induced inflammation and subsequent disease progression as well as other diseases involving phagolysosomal lysis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12989-017-0217-1) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5594487 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-55944872017-09-14 Imipramine blocks acute silicosis in a mouse model Biswas, Rupa Trout, Kevin L. Jessop, Forrest Harkema, Jack R. Holian, Andrij Part Fibre Toxicol Research BACKGROUND: Inhalation of crystalline silica is associated with pulmonary inflammation and silicosis. Although silicosis remains a prevalent health problem throughout the world, effective treatment choices are limited. Imipramine (IMP) is a FDA approved tricyclic antidepressant drug with lysosomotropic characteristics. The aim of this study was to evaluate the potential for IMP to reduce silicosis and block phagolysosome membrane permeabilization. METHODS: C57BL/6 alveolar macrophages (AM) exposed to crystalline silica ± IMP in vitro were assessed for IL-1β release, cytotoxicity, particle uptake, lysosomal stability, and acid sphingomyelinase activity. Short term (24 h) in vivo studies in mice instilled with silica (± IMP) evaluated inflammation and cytokine release, in addition to cytokine release from ex vivo cultured AM. Long term (six to ten weeks) in vivo studies in mice instilled with silica (± IMP) evaluated histopathology, lung damage, and hydroxyproline content as an indicator of collagen accumulation. RESULTS: IMP significantly attenuated silica-induced cytotoxicity and release of mature IL-1β from AM in vitro. IMP treatment in vivo reduced silica-induced inflammation in a short-term model. Furthermore, IMP was effective in blocking silica-induced lung damage and collagen deposition in a long-term model. The mechanism by which IMP reduces inflammation was explored by assessing cellular processes such as particle uptake and acid sphingomyelinase activity. CONCLUSIONS: Taken together, IMP was anti-inflammatory against silica exposure in vitro and in vivo. The results were consistent with IMP blocking silica-induced phagolysosomal lysis, thereby preventing cell death and IL-1β release. Thus, IMP could be therapeutic for silica-induced inflammation and subsequent disease progression as well as other diseases involving phagolysosomal lysis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12989-017-0217-1) contains supplementary material, which is available to authorized users. BioMed Central 2017-09-11 /pmc/articles/PMC5594487/ /pubmed/28893276 http://dx.doi.org/10.1186/s12989-017-0217-1 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Biswas, Rupa Trout, Kevin L. Jessop, Forrest Harkema, Jack R. Holian, Andrij Imipramine blocks acute silicosis in a mouse model |
title | Imipramine blocks acute silicosis in a mouse model |
title_full | Imipramine blocks acute silicosis in a mouse model |
title_fullStr | Imipramine blocks acute silicosis in a mouse model |
title_full_unstemmed | Imipramine blocks acute silicosis in a mouse model |
title_short | Imipramine blocks acute silicosis in a mouse model |
title_sort | imipramine blocks acute silicosis in a mouse model |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5594487/ https://www.ncbi.nlm.nih.gov/pubmed/28893276 http://dx.doi.org/10.1186/s12989-017-0217-1 |
work_keys_str_mv | AT biswasrupa imipramineblocksacutesilicosisinamousemodel AT troutkevinl imipramineblocksacutesilicosisinamousemodel AT jessopforrest imipramineblocksacutesilicosisinamousemodel AT harkemajackr imipramineblocksacutesilicosisinamousemodel AT holianandrij imipramineblocksacutesilicosisinamousemodel |